Advances in Cardiovascular Drug Therapies (Technical Insights)


Regular Price: USD 4,950.00

Special Price USD 3,465.00

30% OFF

* Required Fields

Regular Price: USD 4,950.00

Special Price USD 3,465.00


Be the first to review this product

This research service outlines the key global developments in cardiovascular drug therapies.

Table of Contents

Advances in Cardiovascular Drug Therapies (Technical Insights), Executive SummaryScope and MethodologyScope and SegmentationMethodologyIndustry OverviewBrief Summary of Cardiovascular Drug IndustryKey Findings and Noteworthy DevelopmentsAdvances in Cardiovascular Drug Therapies (Technical Insights), Technology Adoption Factor AnalysisEmerging Trends in Cardiovascular Drug Therapy; Research and DevelopmentCVDs and Drug ClassesEmerging Trends in Cardiovascular Drug TherapyCardiovascular Pharmacogenomics--A Major Trend in Cardiovascular ResearchEmerging Trends in Cardiovascular Biomarkers--Diagnostic; Prognostic; and Therapeutic InsightsEmerging Molecular Therapeutics and Their Impact on CVD Drug DevelopmentStrategic Analysis and RecommendationsAnalysis of Drivers for Cardiovascular Pharmaceutical IndustryImpact of Challenges and Restraints on Cardiovascular PharmaceuticalsProduct Life Cycle Analysis and Strategic RecommendationsOpportunity AnalysisAcquisitions; Partnerships; and Technology Licensing between Companies and Research OrganizationsAdvances in Cardiovascular Drug Therapies (Technical Insights), Global Developments in Cardiovascular DrugsCorporate Developments--WorldBlockbuster Drug to Treat Hypercholesterolemia--USA Novel Antisense Drug for Cholesterol Management--USANovel Direct Acting Aptamer-Based Anticoagulant--USANovel Drug Candidates to Treat Cardiac Reperfusion Induced Heart Failure--IsraelBreakthrough Technology Platform and Novel Drug to Increase HDL Levels--CanadaCardioprotective Effects of a Naturally Occurring Peptide--USANovel Drugs for Acute Coronary Syndrome--CanadaSonolysis-Based tPA Therapy for Ischemic Stroke Patients--USADNA-Based Therapeutic to Treat Angina--USASelective Thyroid Hormone Agonist Lowers LDL Levels--SwedenNovel Drug to Treat Diabetic and Nondiabetic Heart Failure--New ZealandNovel Drug with Better Safety and Tolerability Profile for Atrial Fibrillation--USAAcademic Developments--WorldPPAR-Delta as a Potential Drug Target for Treating Atherosclerosis--USADiscovery of Genetic Link to Bad Cholesterol Raises Hope for Specific Therapy--UKPotential of a Novel Compound to Reduce the Impact of Heart Attack in Humans--USAAdvances in Cardiovascular Drug Therapies (Technical Insights), Intellectual Property Scenario and Key Industry ParticipantsPatent Details and Patent AnalysisCorporate PatentsAcademic PatentsContact DetailsIndustry ContactsUniversity ContactsAdvances in Cardiovascular Drug Therapies (Technical Insights), Decision Support DatabaseDecision Support TablesHypertension Prevalence--World (2002 to 2012)New Cases of Heart Attack--World (2002 to 2012)New Cases of Stroke--World (2002 to 2012)Population Aged 65 Years and Above--World (2002 to 2012)Prevalence of Diabetes--World (2002 to 2012)Pharmaceutical R&D Expenditure--World (2002 to 2012)

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.